Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Verrica Pharmaceuticals's annualizedNet Income for the quarter that ended in Jun. 2026 was $-52.61 Mil. Verrica Pharmaceuticals's average total tangible assets for the quarter that ended in Jun. 2026 was $37.40 Mil. Therefore, Verrica Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -140.67%.
The historical rank and industry rank for Verrica Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
VRCA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -351.65 Med: -52.69 Max: -35.19
Current: -42.83
During the past 10 years, Verrica Pharmaceuticals's highest Return-on-Tangible-Asset was -35.19%. The lowest was -351.65%. And the median was -52.69%.
VRCA's Return-on-Tangible-Asset is ranked worse than 54.84% of 1415
companies
in the Biotechnology industry
Industry Median: -35.49
vs VRCA: -42.83
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Verrica Pharmaceuticals Return-on-Tangible-Asset Related Terms
Verrica Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Verrica Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRCA vs HRTX, RLYB, CSBR: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Verrica Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -140.67% mean?
Verrica Pharmaceuticals (VRCA) has a Return-on-Tangible-Asset of -140.67% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Verrica Pharmaceuticals and its competitors. According to the industry distribution chart, Verrica Pharmaceuticals ranks #776 out of 1415 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Verrica Pharmaceuticals' Return-on-Tangible-Asset too high?
Verrica Pharmaceuticals' current Return-on-Tangible-Asset is -140.67%. Based on the distribution chart, Verrica Pharmaceuticals ranks #776 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Verrica Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Return-on-Tangible-Asset compare to HRTX and RLYB?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #776 out of 1415 companies for Return-on-Tangible-Asset. This places Verrica Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Verrica Pharmaceuticals and its competitors. Verrica Pharmaceuticals's current Return-on-Tangible-Asset is -140.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (VRCA) is currently considered Possible Value Trap. The stock's GF Value™ is $10.45, compared to a current price of $5.20 — trading 50.2% below its estimated fair value. The current Return-on-Tangible-Asset is -140.67%. Verrica Pharmaceuticals' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Verrica Pharmaceuticals (VRCA), the current Return-on-Tangible-Asset is -140.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (VRCA) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.20 is trading 50.2% below its estimated GF Value™ of $10.45.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for VRCA:
Return-on-Tangible-Asset: -140.67%
GF Value™: $10.45 vs. price of $5.20 (50.2% below fair value)
No single metric tells the full story. See the VRCA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
45GF Score
Get the complete analysis for VRCA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCA has been successfully added to your 
